Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Thomas G. Gant, Carlsbad US

Thomas G. Gant, Carlsbad, CA US

Patent application numberDescriptionPublished
20080234257SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY - Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, attention deficit hyperactivity disorder, fibromyalgia, irritable bowel syndrome, and/or premature ejaculation are described.09-25-2008
20080241289PREPARATION AND UTILITY OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS - Disclosed herein are non-nucleoside reverse transcriptase inhibitors having structural Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and the methods of their use thereof.10-02-2008
20080242687SUBSTITUTED PYRIMIDINES - Disclosed herein are substituted pyrimidine-based endothelin modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.10-02-2008
20080255036SUBSTITUTED THIOPHENES - Disclosed herein are substituted pyrimidine-based endothelin modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.10-16-2008
20080255200SUBSTITUTED BENZIMIDAZOLES - Disclosed herein are substituted benzimidazole-based proton pump modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.10-16-2008
20080262086SUBSTITUTED ANTHRANILIC ACIDS - Disclosed herein are substituted anthranilic acids, pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and medical use of such compounds for the treatment and/or management of hypertension, edema associated with congestive heart failure, hepatic disease, renal disease including nephrotic syndrome, or clearance of toxic substances from the body.10-23-2008
20080268071SUBSTITUTED CYCLOHEXANONES - Disclosed herein are substituted cyclohexanone-based NMDA receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.10-30-2008
20080280886SUBSTITUTED UREAS - Disclosed herein are urea-based 5-HT receptor modulators, pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and medical use of such compounds for the treatment and/or management of 5-HT receptor-mediated disorders.11-13-2008
20080280991SUBSTITUTED NAPHTHALENES - Disclosed herein are substituted naphthalene-based melatonin (MT) receptor modulators and/or 5-HT receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.11-13-2008
20080300316SUBSTITUTED PHENETHYLAMINES - Disclosed herein are substituted phenethylamine alpha adrenergic receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.12-04-2008
20080312247SUBSTITUTED PIPERAZINES - Disclosed herein are substituted piperazine late Na12-18-2008
20080319026SUBSTITUTED N-ARYL PYRIDINONES - Disclosed herein are substituted N-Aryl pyridinone fibrotic inhibitors and/or collagen infiltration modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.12-25-2008
20090005309SUBSTITUTED PIPERIDINES - Disclosed herein are substituted piperidine-based muscarinic receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.01-01-2009
20090005431SUBSTITUTED PYRROLIDINES - Disclosed herein are substituted pyrrolidine-based muscarinic receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.01-01-2009
20090018207SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY - Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.01-15-2009
20090022706SUBSTITUTED CYCLOHEXENES - Disclosed herein are substituted cyclohexene TLR4 signaling pathway modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.01-22-2009
20090023765SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY - Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.01-22-2009
20090028873SUBSTITUTED CYCLOHEXANOLS - Disclosed herein are substituted cyclohexanol opioid receptor modulators and/or neurotransmitter reuptake modulators of Formula I or Formula II, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.01-29-2009
20090068168SUBSTITUTED AMINO ALCOHOLS - Disclosed herein are substituted amino alcohol anti-mycobacterial agents and/or chelation therapy agents of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.03-12-2009
20090176792SUBSTITUTED DIBENZHYDRYLPIPERAZINES - The present invention relates to new dibenzhydrylpiperazine modulators of histamine receptors, pharmaceutical compositions thereof, and methods of use thereof.07-09-2009
20090191183SUBSTITUTED INDOLES - Disclosed herein are substituted indole cysteinyl leukotriene receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.07-30-2009
20090202540SUBSTITUTED OXAZAPHOSPHORINES - The present invention relates to new oxazaphosphorine alkylating agents and/or immuno-suppressive agents, pharmaceutical compositions thereof, and methods of use thereof.08-13-2009
20090203763SUBSTITUTED BENZHYDRYLETHERS - Disclosed herein are substituted benzhydrylethers of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of their use thereof.08-13-2009
20090209550SUBSTITUTED TRIAZOLOPYRIDINES - Disclosed herein are substituted triazolopyridine serotonin reuptake modulators and/or 5-HT receptor modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.08-20-2009
20090209592INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES - Chemical syntheses and medical uses of novel inhibitors of the gastric H08-20-2009
20090215831INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES - Chemical syntheses and medical uses of novel inhibitors of the gastric H08-27-2009
20090247628SUBSTITUTED PHENYLCYCLOHEXYLGLYCOLATES - Disclosed herein are substituted phenylcyclohexylglycolate-based muscarinic acetylcholine receptor modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.10-01-2009
20090258897Substituted benzimidazoles - Disclosed herein are substituted benzimidazole-based proton pump modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.10-15-2009
20090270469SUBSTITUTED OXAZOLIDINONES - The present invention relates to new oxazolidinone modulators of skeletal muscle function and tone, pharmaceutical compositions thereof, and methods of use thereof.10-29-2009
20090285811ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE GLUCOCORTICOID STEROIDS - The present invention relates to new glucocorticoid steroid modulators of glucocorticoid receptor, pharmaceutical compositions thereof, and methods of use thereof.11-19-2009
20090291958Substituted PDE5 inhibitors - Provided herein are substituted PDE5 inhibitors of Formula 1, and processes of preparation and pharmaceutical compositions thereof. Also provided are methods of their use for the treatment and/or management of hypertension, erectile dysfunction, and/or the inability to maintain improved erectile function.11-26-2009
20090312435SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY - Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.12-17-2009
20100009950SUBSTITUTED ETHANOLAMINES - The present invention relates to new substituted ethanolamine adrenergic receptor modulators, pharmaceutical compositions thereof, and methods of use thereof.01-14-2010
20100016365SUBSTITUTED 4-AMINO-PIPERIDINES - The present invention relates to new substituted 4-amino-piperidine opioid receptor modulators, pharmaceutical compositions thereof, and methods of use thereof.01-21-2010
201000550722-OXO-1,2-DIHYDRO-QUINOLINE MODULATORS OF IMMUNE FUNCTION - The present invention relates to new 2-oxo-1,2-dihydro-quinoline modulators of immune function, pharmaceutical compositions thereof, and methods of use thereof.03-04-2010
20100056546SULFONYLUREA INHIBITORS OF ATP-SENSITIVE POTASSIUM CHANNELS - The present invention relates to new sulfonylurea inhibitors of ATP-sensitive potassium channels, pharmaceutical compositions thereof, and methods of use thereof.03-04-2010
20100069356DIBENZOTHIAZEPINE MODULATORS OF DOPAMINE, ALPHA ADRENERGIC, AND SEROTONIN RECEPTORS - The present invention relates to new dibenzothiazepine modulators of D1 receptors, D2 receptors, alpha-1 adrenergic receptors, alpha-2 adrenergic receptors, H1 receptors, 5-HT1A receptors, and/or 5-HT2 receptors, pharmaceutical compositions thereof, and methods of use thereof.03-18-2010
20100069399ARYLPIPERAZINE MODULATORS OF D2 RECEPTORS, 5-HT1A RECEPTORS, AND/OR 5-HT2A RECEPTORS - The present invention relates to new arylpiperazine modulators of D2 receptors, 5-HT1A receptors, and/or 5-HT2A receptors, pharmaceutical compositions thereof, and methods of use thereof.03-18-2010
20100074973THIOXANTHENE MODULATORS OF DOPAMINE D2 RECEPTORS - The present invention relates to new thioxanthene modulators of dopamine D03-25-2010
20100075916SUBSTITUTED QUINAZOLINE INHIBITORS OF GROWTH FACTOR RECEPTOR TYROSINE KINASES - The present invention relates to new substituted quinazoline inhibitors of vascular endothelial growth factor receptor tyrosine kinase, epidermal growth factor receptor tyrosine kinase, and/or REarranged during Transfection tyrosine kinase, pharmaceutical compositions thereof, and methods of use thereof.03-25-2010
20100075935XANTHINE MODULATORS OF ADENOSINE A1 RECEPTOR - The present invention relates to new xanthine modulators of adenosine A03-25-2010
20100075950PHENYLPROPANONE MODULATORS OF DOPAMINE RECEPTOR - The present invention relates to new phenylpropanone modulators of dopamine receptors, serotonin receptors, and/or nicotinic acetylcholine receptors, pharmaceutical compositions thereof, and methods of use thereof.03-25-2010
20100076074CARBAMATE REDUCERS OF SKELETAL MUSCLE TENSION - The present invention relates to new carbamate skeletal muscle relaxants, pharmaceutical compositions thereof, and methods of use thereof.03-25-2010
20100076087METHODS OF REDUCTION OF INTERPATIENT VARIABILITY - Disclosed herein are methods for the reduction of inter-patient variability of a drug, such as in one or more parameters including half-life (t03-25-2010
20100087364TROPINE MODULATORS OF 5-HT3 RECEPTOR - The present invention relates to new tropine modulators of 5-HT3 receptor, pharmaceutical compositions thereof, and methods of use thereof.04-08-2010
20100087455SUBSTITUTED XANTHINE COMPOUNDS - The present invention relates to new substituted xanthine-based agents, pharmaceutical compositions thereof, and methods of use thereof.04-08-2010
20100093758PYRIDINE SULFONAMIDE MODULATORS OF ENDOTHELIN-A RECEPTOR - The present invention relates to new pyridine sulfonamide modulators of endothelin-A receptor, pharmaceutical compositions thereof, and methods of use thereof.04-15-2010
20100099666PHENOTHIAZINE MODULATORS OF H1 RECEPTOR AND D2 RECEPTOR - The present invention relates to new phenothiazine modulators of H1 receptors and/or D2 receptors, pharmaceutical compositions thereof, and methods of use thereof.04-22-2010
20100099701ISOQUINOLINONE MODULATORS OF 5-HT3 RECEPTORS - The present invention relates to new isoquinolinone modulators of 5-HT3 receptors, pharmaceutical compositions thereof, and methods of use thereof.04-22-2010
20100105720PREPARATION AND UTILITY OF SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS WITH HYPNOTIC EFFECTS - The present disclosure is directed to modulators of GABA04-29-2010
20100105755SUBSTITUTED BENZAMIDE MODULATORS OF DOPAMINE RECEPTOR - The present invention relates to new substituted benzamide modulators of dopamine receptor, pharmaceutical compositions thereof, and methods of use thereof.04-29-2010
20100111901TRIAZOLE INHIBITORS OF AROMATASE - The present invention relates to new triazole modulators of aromatase activity, pharmaceutical compositions thereof, and methods of use thereof.05-06-2010
20100113359DIMETHYLPHENOXY MODULATORS OF VIRAL PROTEASE ACTIVITY AND/OR PARASITIC ENZYME ACTIVITY - The present invention relates to new dimethylphenoxy inhibitors of viral protease or parasitic enzymes, pharmaceutical compositions thereof, and methods of use thereof.05-06-2010
20100113405METHYLINDAZOLE MODULATORS OF 5-HT3 RECEPTORS - The present invention relates to new methylindazole modulators of 5-HT3 receptor activity, pharmaceutical compositions thereof, and methods of use thereof.05-06-2010
20100113431N-METHYL PIPERAZINE MODULATORS OF H1 RECEPTOR - The present invention relates to new N-methyl piperazine modulators of H1 receptor activity, pharmaceutical compositions thereof, and methods of use thereof.05-06-2010
20100113432PHENOTHIAZINE MODULATORS OF D2 RECEPTORS AND 5-HT2 RECEPTORS - The present invention relates to new phenothiazine modulators of D2 receptor activity and/or 5-HT2 receptor activity, pharmaceutical compositions thereof, and methods of use thereof.05-06-2010
20100113478INDOLONE MODULATORS OF 5-HT3 RECEPTOR - The present invention relates to new indolone modulators of 5-HT3 receptor, pharmaceutical compositions thereof, and methods of use thereof.05-06-2010
20100113496PIPERIDINE MODULATORS OF VMAT2 - The present invention relates to new piperidine modulators of VMAT2, nicotinic acetylcholine receptors, and/or μ-opioid receptors, pharmaceutical compositions thereof, and methods of use thereof.05-06-2010
20100113606AMINOPROPANOL MODULATORS OF BETA-1 ADRENERGIC RECEPTOR - The present invention relates to new aminopropanol modulators of beta-1 adrenergic receptor activity, pharmaceutical compositions thereof, and methods of use thereof.05-06-2010
20100119508PHENYLACETIC ACID INHIBITORS OF CYCLOOXYGENASE - The present invention relates to new phenylacetic acid inhibitors of cyclooxygenase activity, pharmaceutical compositions thereof, and methods of use thereof.05-13-2010
201001196223H-BENZOOXAZOL-2-ONE MODULATORS OF D2 RECEPTOR AND/OR 5-HT1A RECEPTOR - The present invention relates to new 3H-benzooxazol-2-one modulators of D2 receptors and/or 5-HT1A receptors, pharmaceutical compositions thereof, and methods of use thereof.05-13-2010
20100119623IMIDAZOLYL MODULATORS OF 5-HT3 RECEPTORS - The present invention relates to new imidazolyl modulators of 5-HT3 receptors, pharmaceutical compositions thereof, and methods of use thereof.05-13-2010
20100119624BENZISOXAZOLE MODULATORS OF D2 RECEPTOR AND/OR 5-HT2A RECEPTOR - The present invention relates to new benzisoxazole modulators of D2 receptors and/or 5-HT2A receptors, pharmaceutical compositions thereof, and methods of use thereof.05-13-2010
20100120733STEROID MODULATORS OF GLUCOCORTICOID RECEPTOR - The present invention relates to new steroid modulators of glucocorticoid receptor activity, pharmaceutical compositions thereof, and methods of use thereof.05-13-2010
20100120744ACETAMIDOPROPANE MODULATORS OF NMDA RECEPTORS - The present invention relates to new acetamidopropane modulators of NMDA receptor, pharmaceutical compositions thereof, and methods of use thereof.05-13-2010
20100120756PHENOTHIAZINE MODULATORS OF H1 RECEPTORS - The present invention relates to new phenothiazine modulators of H1 receptors, pharmaceutical compositions thereof, and methods of use thereof.05-13-2010
20100120861BENZOIC ACID INHIBITORS OF ATP-SENSITIVE POTASSIUM CHANNELS - The present invention relates to new benzoic acid inhibitors of ATP-sensitive potassium channel activity, pharmaceutical compositions thereof, and methods of use thereof.05-13-2010
20100120917BUTYLAMMONIUM MODULATORS OF FATTY ACID TRANSPORT - The present invention relates to new butylammonium modulators of fatty acid transport, and/or removal of toxic acyl-CoA compounds, pharmaceutical compositions thereof, and methods of use thereof05-13-2010
20100121067PREPARATION AND UTILITY OF SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS WITH HYPNOTIC EFFECTS - The present disclosure is directed to modulators of GABA05-13-2010
20100124541HYDROXYADAMANTYL INHIBITORS OF DIPEPTIDYLPEPTIDASE IV - The present invention relates to new hydroxyadamantyl inhibitors of dipeptidylpeptidase IV activity, pharmaceutical compositions thereof, and methods of use thereof.05-20-2010
20100124550AMIDE INHIBITORS OF RENIN - The present invention relates to new amide inhibitors of renin, pharmaceutical compositions thereof, and methods of use thereof05-20-2010
20100125067SULFONAMIDE INHIBITORS OF CARBONIC ANHYDRASE II - The present invention relates to new sulfonamide inhibitors of carbonic anhydrase II, pharmaceutical compositions thereof, and methods of use thereof.05-20-2010
20100125085PYRIDOINDOLE MODULATORS OF NMDA RECEPTOR AND ACETYLCHOLINESTERASE - The present invention relates to new pyridoindole modulators of NMDA receptors, AMPA receptors, and/or L-type calcium channels, and/or inhibitors of acetylcholinesterase, pharmaceutical compositions thereof, and methods of use thereof.05-20-2010
20100125094PYRROLIDINYL MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS - The present invention relates to new pyrrolidinyl modulating nicotinic acetylcholine receptor compounds, pharmaceutical compositions thereof, and methods of use thereof.05-20-2010
20100129311PHENYLALANINE AMIDE INHIBITORS OF ATP-SENSITIVE POTASSIUM CHANNELS - The present invention relates to new phenylalanine amide inhibitors of ATP-sensitive potassium channels, pharmaceutical compositions thereof, and methods of use thereof.05-27-2010
20100129366THIAZOLE INHIBITORS OF CYCLOOXYGENASE - The present invention relates to new thiazole inhibitors of cyclooxygenase, pharmaceutical compositions thereof, and methods of use thereof.05-27-2010
20100130480BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 - The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.05-27-2010
20100130528ADAMANTANE MODULATORS OF NMDA RECEPTOR AND/OR 5HT3 RECEPTOR - The present invention relates to new adamantane modulators of NMDA receptors and/or 5HT3 receptors, pharmaceutical compositions thereof, and methods of use thereof.05-27-2010
20100130543PYRAZOLE CARBOXAMIDE INHIBITORS OF FACTOR XA - The present invention relates to new pyrazole carboxamide inhibitors of factor Xa, pharmaceutical compositions thereof, and methods of use thereof.05-27-2010
20100130582INDOLINONE MODULATORS OF DOPAMINE RECEPTOR - The present invention relates to new indolinone modulators of dopamine receptor, pharmaceutical compositions thereof, and methods of use thereof.05-27-2010
20100130615SULFONYLUREA INHIBITORS OF ATP-SENSITIVE POTASSIUM CHANNELS - The present invention relates to new sulfonylurea inhibitors of ATP-sensitive potassium channels, pharmaceutical compositions thereof, and methods of use thereof.05-27-2010
20100130617ETHANOLAMINE MODULATORS OF NMDA RECEPTOR AND MUSCARINIC ACETYLCHOLINE RECEPTOR - The present invention relates to new ethanolamine modulators of NMDA receptors and/or muscarinic acetylcholine receptors, pharmaceutical compositions thereof, and methods of use thereof.05-27-2010
20100135956STEROID MODULATORS OF PROGESTERONE RECEPTOR AND/OR GLUCOCORTICOID RECEPTOR - The present invention relates to new steroid modulators of progesterone receptor activity and/or glucocorticoid receptor activity, pharmaceutical compositions thereof, and methods of use thereof.06-03-2010
20100137244PREPARATION AND UTILITY OF HMG-COA REDUCTASE INHIBITORS - Chemical syntheses and medical uses of novel modulators of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and diastereomeric mixtures of isomers, individual diastereomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment and/or management of hypercholesterolemia, dyslipidemia, coronary artery disease, atherosclerosis, metabolic syndrome, a hyperproliferative disease such as colorectal cancer, prostate cancer, and melanoma, a neurodegenerative disease such as cerebral ischemia, Alzheimer's disease, and Parkinson's disease are described.06-03-2010
20100137268PHTHALAZINONE MODULATORS OF H1 RECEPTORS AND/OR LTC4 RECEPTORS - The present invention relates to new phthalazinone modulators of H1 receptor activity and/or modulators of LTC4 production, pharmaceutical compositions thereof, and methods of use thereof.06-03-2010
20100137332PIPERAZINE MODULATORS OF NK-1 RECEPTORS - The present invention relates to new piperazine modulators of NK-1 receptors, pharmaceutical compositions thereof, and methods of use thereof.06-03-2010
20100143287TRIFLUOROMETHYLPHENYL MODULATORS OF CALCIUM-SENSING RECEPTOR - The present invention relates to new trifluoromethylphenyl modulators of calcium-sensing receptor, pharmaceutical compositions thereof, and methods of use thereof.06-10-2010
20100143295QUINAZOLINE INHIBITORS OF EGFR TYROSINE KINASE - The present invention relates to new quinazoline inhibitors of EGFR tyrosine kinase, pharmaceutical compositions thereof, and methods of use thereof.06-10-2010
20100143296PODOPHYLLOTOXIN INHIBITORS OF TOPOISOMERASE II - The present invention relates to new podophyllotoxin inhibitors of topoisomerase II, pharmaceutical compositions thereof, and methods of use thereof.06-10-2010
20100143354TRIAZINE DNA MODIFIERS - The present invention relates to new triazine DNA modifiers, pharmaceutical compositions thereof, and methods of use thereof06-10-2010
20100143505INDANONE INHIBITORS OF ACETYLCHOLINESTERASE - The present invention relates to new indanone inhibitors of acetylcholinesterase, pharmaceutical compositions thereof, and methods of use thereof.06-10-2010
20100143507CARBOXYLIC ACID INHIBITORS OF HISTONE DEACETYLASE, GABA TRANSAMINASE AND SODIUM CHANNEL - The present invention relates to new carboxylic acid inhibitors of histone deacetylase, GABA transaminase, and/or sodium channel activity, pharmaceutical compositions thereof, and methods of use thereof.06-10-2010
20100144657PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS - The present invention relates to new phenylpiperidine modulators of opioid μ-receptors, pharmaceutical compositions thereof, and methods of use thereof.06-10-2010
20100144880AMINO ACID INHIBITORS OF PLASMIN - The present invention relates to new amino acid inhibitors of plasmin, pharmaceutical compositions thereof, and methods of use thereof06-10-2010
20100150896DIAMINOQUINAZOLINE INHIBITORS OF DIHYDROFOLATE REDUCTASE - The present invention relates to new diaminoquinazoline inhibitors of dihydrofolate reductase activity, pharmaceutical compositions thereof, and methods of use thereof.06-17-2010
20100150899PYRAZOLINONE SCAVENGERS OF FREE RADICAL - The present invention relates to new pyrazolinone scavengers of free radicals, pharmaceutical compositions thereof, and methods of use thereof.06-17-2010
20100152224SCOPINE MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR - The present invention relates to new scopine modulators of muscarinic acetylcholine receptors, pharmaceutical compositions thereof, and methods of use thereof.06-17-2010
20100152283TETRAHYDROCANNABINOL MODULATORS OF CANNABINOID RECEPTORS - The present invention relates to new tetrahydrocannabinol modulators of cannabinoid receptors, pharmaceutical compositions thereof, and methods of use thereof.06-17-2010
20100159033BENZISOXAZOLE MODULATORS OF D2 RECEPTOR, AND/OR 5-HT2A RECEPTOR - The present invention relates to new benzisoxazole modulators of D2 receptors and/or 5-HT2A receptors, pharmaceutical compositions thereof, and methods of use thereof.06-24-2010
20100159034PYRROLIDINONE INHIBITORS OF PDE-4 - The present invention relates to new pyrrolidinone inhibitors of PDE-4 activity, pharmaceutical compositions thereof, and methods of use thereof.06-24-2010
20100160271BICYCLIC MODULATORS OF H1 RECEPTORS - The present invention relates to new bicyclic modulators of H1 receptor activity, pharmaceutical compositions thereof, and methods of use thereof06-24-2010
20100160272OXEPINE MODULATORS OF H1 RECEPTORS AND/OR INHIBITORS OF MAST CELL DEGRANULATION - The present invention relates to new oxepine modulators of H1 receptors and/or inhibitors of mast cell degranulation, pharmaceutical compositions thereof, and methods of use thereof.06-24-2010
20100160338BENZENESULFONAMIDE MODULATORS OF ALPHA-1A ADRENERGIC RECEPTORS - The present invention relates to new benzenesulfonamide modulators of alpha-1A adrenergic receptors, pharmaceutical compositions thereof, and methods of use thereof.06-24-2010
20100160347PYRIDO[1,2-a]PYRIMIDIN-4-ONE INHIBITORS OF MAST CELL DEGRANULATION - The present invention relates to new pyrido[1,2-a]pyrimidin-4-one inhibitors of mast cell degranulation, pharmaceutical compositions thereof, and methods of use thereof.06-24-2010
201001604463,4-DIMETHOXYPHENETHYLAMINE MODULATORS OF L-TYPE CALCIUM CHANNEL - The present invention relates to new 3,4-dimethoxyphenethylamine modulators of L-type calcium channel activity, pharmaceutical compositions thereof, and methods of use thereof.06-24-2010
20100166887DIBENZO[b,e][1,4]DIAZEPINE MODULATORS OF DOPAMINE RECEPTORS, SEROTONIN RECEPTORS, ADRENERGIC RECEPTORS, ACETYLCHOLINE RECEPTORS, AND/OR HISTAMINE RECEPTORS - The present invention relates to new dibenzo[b,e][1,4]diazepine modulators of dopamine receptors, serotonin receptors, adrenergic receptors, acetylcholine receptors, and/or histamine receptors, pharmaceutical compositions thereof, and methods of use thereof.07-01-2010
20100167988ETHOXYPHENYLMETHYL INHIBITORS OF SGLT2 - The present invention relates to new ethoxyphenylmethyl modulators of SGLT2, pharmaceutical compositions thereof, and methods of use thereof.07-01-2010
20100167989ISOPROPOXYPHENYLMETHYL INHIBITORS OF SGLT2 - The present invention relates to new isopropoxyphenylmethyl inhibitors of SGLT2, pharmaceutical compositions thereof, and methods of use thereof.07-01-2010
201001680867,8,10,10A-TETRAHYDRO-6H-BENZO[C]CHROMEN-9(6AH)-ONE MODULATORS OF CANNABINOID RECEPTORS - The present invention relates to new 7,8,10,10a-tetrahydro-6H-benzo[c]chromen-9(6aH)-one modulators of cannabinoid receptors, pharmaceutical compositions thereof, and methods of use thereof.07-01-2010
20100172916SUBSTITUTED HYDROXYPHENYLAMINE COMPOUNDS - The present invention relates to new substituted hydroxyphenylamine based modulators of hormone and/or pigment levels, pharmaceutical compositions thereof, and methods of use thereof.07-08-2010
20100222257SUBSTITUTED PHENETHYLAMINES - Disclosed herein are substituted phenethylamine alpha adrenergic receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.09-02-2010
20100234388SUBSTITUTED PDE5 INHIBITORS - Provided herein are substituted PDE5 inhibitors of Formula (1), and processes of preparation and pharmaceutical compositions thereof. Also provided are methods of their use for the treatment and/or management of hypertension, erectile dysfunction, and/or the inability to maintain improved erectile function. The compounds are deuterated tadalafil derivatives.09-16-2010
20100266711THIENOBENZODIAZEPINE MODULATORS OF D1 RECEPTOR, D2 RECEPTOR, AND/OR 5-HT2 RECEPTOR - The present invention relates to new thienobenzodiazepine modulators of D1 receptors, D2 receptors, and/or 5-HT2 receptors, pharmaceutical compositions thereof, and methods of use thereof.10-21-2010
20100280086SUBSTITUTED THIOPHENES - Disclosed herein are substituted pyrimidine-based endothelin modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.11-04-2010
20100286124PROP-2-YN-1-AMINE INHIBITORS OF MONOAMINE OXIDASE TYPE B - The present invention relates to new prop-2-yn-1-amine inhibitors of monoamine oxidase type B activity, pharmaceutical compositions thereof, and methods of use thereof.11-11-2010
201002911511-METHYLPYRAZOLE MODULATORS OF SUBSTANCE P, CALCITONIN GENE-RELATED PEPTIDE, ADRENERGIC RECEPTOR, AND/OR 5-HT RECEPTOR - The present invention relates to new 1-methylpyrazole modulators of substance P release, calcitonin gene-related peptide activity, adrenergic receptor activity, and/or 5-HT receptor activity, pharmaceutical compositions thereof, and methods of use thereof.11-18-2010
20110054020NAPTHYLENE INHIBITORS OF CYCLOOXYGENASE - The present invention relates to new napthylene inhibitors of cyclooxygenase activity, pharmaceutical compositions thereof, and methods of use thereof03-03-2011
20110091459IMIDAZOLE MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M3 - The present invention relates to new imidazole modulators of M3 muscarinic acetylcholine receptor activity, pharmaceutical compositions thereof, and methods of use thereof.04-21-2011
20110123555PREPARATION AND UTILITY OF CCR5 INHIBITORS - Disclosed herein are substituted 8-azabicyclo[3.2.1]octane-based anti-infective agents of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.05-26-2011
20110130424SUBSTITUTED PHENYLPIPERIDINES WITH SEROTONINERGIC ACTIVITY AND ENHANCED THERAPEUTIC PROPERTIES - Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.06-02-2011
20110136834INHIBITORS OF E1 ACTIVATING ENZYMES - This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.06-09-2011
20110136914SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY - Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.06-09-2011
20110160154SUBSTITUTED PIPERAZINES - Disclosed herein are substituted piperazine late Na06-30-2011
20110160244PHENYLPIPERIDINE MODULATORS OF MU-OPIOID RECEPTOR - The present invention relates to new phenylpiperidine modulators of μ-opioid receptors, pharmaceutical compositions thereof, and methods of use thereof.06-30-2011

Patent applications by Thomas G. Gant, Carlsbad, CA US